RICHMOND, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that they will open their doors to the general public on the afternoon of Friday, June 10th, 2016. The open house will commence with a morning research preview for healthcare professionals, presented by thought leader Dr. Dylan Edwards.  Dr. Edwards will share his preliminary findings on how using Ekso GT, the only exoskeleton cleared for stroke, is helping his patients relearn to walk. Afternoon activities include a unique opportunity to experience a range of exoskeleton technologies first hand, tour Ekso Bionics’ historic Henry Ford factory facility and watch live exoskeleton demonstrations.

"We are excited to give our neighbors, current and prospective customers, students, investors and media the opportunity to tour our US headquarters and observe the important work we do as an industry leader," Tom Looby, chief executive officer, and president, of Ekso Bionics said. “We are in the business of helping people achieve a better quality of life by amplifying their potential with our exoskeleton technology.  We are honored to be able to share the vision and the business with our Bay Area neighbors.”

The open house, which runs from 12:00–5:00PM, will include guided tours every hour to showcase the history of exoskeletons, clinical demonstrations, 3D printing stations, engineering and labs presentations, and our new industrial exoskeleton department. To reserve your spot or learn more about the event please contact jhenderson@eksobionics.com or RSVP at links below.

Presentation for healthcare professionals: https://discussionwithdrdylanedwards.eventbrite.com 

Public open house: https://www.eventbrite.com/e/ekso-bionics-open-house-tickets-24665868276 

About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities.

The company is headquartered in the Bay Area and is listed on the OTCQB under the symbol EKSO. For more information, visit: www.eksobionics.com.

About Ekso™ GT
Ekso GT is the first FDA cleared exoskeleton cleared for use with stroke, and spinal cord injury levels to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 55 million steps in over 120 rehabilitation institutions around the world

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

Media Contact:
Heidi Darling, Director of Marketing Communications
Phone: 510-984-1761 x317
hdarling@eksobionics.com

Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com